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Twelve patients were treated with omadacycline (OMC) as part of
a multidrug regimen for Mycobacterium abscessus. The majority
of infections were of pulmonary origin (7/12; 58.3%). The median
(interquartile range) duration of OMC was 6.2 (4.2–11.0) months.
Clinical success occurred in 9/12 (75.0%) patients. Three patients
experienced a possible adverse effect while on therapy.
Keywords.
Mycobacterium abscessus; omadacycline;
rapidly growing nontuberculous mycobacteria.
Nontuberculous mycobacteria (NTM) are opportunistic pathogens that are intrinsically resistant to many
antimicrobials and lead to significant health care costs, morbidity, and mortality [1]. Specifically, Mycobacterium abscessus
complex (composed of the subspecies M. abscessus, M. bolletii,
and M. massiliense) is the most drug-resistant and pathogenic
of the rapidly growing mycobacteria (RGM) and is very challenging to treat, partly owing to the varying resistance mechanisms between these subspecies (including to macrolides,
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METHODS

This was a multicenter, retrospective, observational case series
at 6 geographically distinct medical centers in the United States
in which OMC was initiated between January and August 2020.
We included individuals aged ≥18 years with ≥1 M. abscessus–
positive culture, in the setting of clinical suspicion for either
pulmonary or extrapulmonary infection, who received OMC
for ≥3 months with ≥3 months of documented NTM follow-up
after OMC initiation. Patients were still included if negative
circumstances (eg, OMC discontinued due to AE, death) precluded insufficient exposure or duration (<3 months) of OMC
continuation and/or follow-up.
Early clinical success was defined as a composite of survival, lack of clinical/radiographic worsening, lack of alteration
of OMC therapy due to concerns for treatment failure, lack of
microbiologic relapse (if patient has achieved culture conversion or microbiologic clearance and cultures were drawn), and
lack of culture persistence for 3 consecutive positive cultures
following OMC initiation (if patient has not had at least 2 negative cultures and cultures were drawn), which was evaluated
throughout the required follow-up. We also reported intentions
for OMC utilization and incidence of AE.
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an important therapeutic for NTM treatment, if susceptible,
and also available in an oral formulation) and prolonged treatment durations that are typically expensive [2]. Furthermore,
a lack of clinical trials and minimally effective oral therapies
lead to variations in how patients are treated and further compromise patient satisfaction, respectively [3]. It is crucial that
novel antibiotics with optimal oral bioavailability, minimal
adverse effects (AEs), and effectiveness against all subspecies
of M. abscessus complex be discovered, developed, and clinically evaluated.
Omadacycline (OMC), a semisynthetic aminomethylcycline
within the tetracycline (TCN) class, is available both in intravenous and oral formulations and is Food and Drug
Administration (FDA) approved for community-acquired
pneumonia and acute bacterial skin and skin structure infections
[4]. Recent investigations have shown potent in vitro activity
of OMC against drug-resistant M. abscessus complex clinical
isolates, with observed minimum inhibitory concentration
(MIC)90 values similar to tigecycline (TGC) and eravacycline
(ERV; intravenous-only glycylcycline and fluorocycline, respectively, within the TCN class) [5, 6]. However, limited studies
have reported patient outcomes of those treated with OMC for
M. abscessus infections [7]. The objective of this case series was
to describe preliminary real-world experience of OMC for the
treatment of M. abscessus infections.

RESULTS

Overall, 12 patients met inclusion criteria. Four individuals
were excluded due to insufficient exposure to OMC (3/4) and/
or insufficient duration of follow-up (4/4). Included individuals had a median age (interquartile range [IQR]) of 58 (54–63)
years, they had a median body mass index (IQR) of 23.6 (21.1–
28.9) kg/m2, 50.0% were female, and 91.7% were Caucasian.
Common comorbidities in those with nontuberculous mycobacterial pulmonary disease (NTM-PD) included interstitial
lung disease (5/7; 71.4%), chronic obstructive pulmonary disease (2/7; 28.6%), asthma (2/7; 28.6%), and solid organ malignancy and/or acute myeloid leukemia (2/7; 28.6%), while
no patients had cystic fibrosis or autoimmune disease. The
majority of patients had insurance coverage through private
entities (6/12; 50.0%), followed by Medicare (3/12; 25.0%;
evaluated due to insurance coverage associated with selection
of medications), and were treated with OMC strictly in the outpatient setting (10/12; 83.3%). Of patients included in this analysis, 5/12 (41.7%) had surgical interventions (debridement and/
or incision and drainage).
The source of infection was primarily NTM-PD (7/12;
58.3%), followed by bone/joint (2/12; 16.7%). Three other
extrapulmonary sites of infection involved an intra-abdominal
infection, a skin and soft tissue infection, and an infected intravenous catheter. Of those with NTM-PD, the radiographic
pattern was 57.1% (4/7) nodular bronchiectatic and 42.9%
(3/7) fibrocavitary. Disseminated infection occurred in 2/12
(16.7%) of patients. The initial M. abscessus isolates were most
commonly isolated from expectorated sputum (4/12; 33.3%),
wound/tissue (4/12; 33.3%), or induced sputum (1/12; 8.3%).
Of all included cases, 7/12 (58.3%) of isolates underwent
subspeciation (6/7; 85.7% subspecies M. abscessus, 1/7; 14.3%
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subspecies M. massiliense). Erm gene genotyping (genes that
can express inducible macrolide resistance) was conducted in
9/12 (75.0%) isolates, with functional erm gene detected in 6/9
(66.7%) [2].
Before OMC initiation, antibiotic therapy was administered
in 10/12 (83.3%) cases, for a median (IQR) of 4.7 (3.4–12.7)
months (these data were calculated based on 11 patients, as data
were not available for 1 patient). Mycobacterial cultures were
positive at the time of OMC initiation in 6/9 (66.7%) patients
for whom this information was known. Only a single isolate
underwent MIC determination for OMC, which was 0.5 mcg/
mL. However, TIG MICs were reported for 11/12 (91.7%) isolates (range, 0.06–1 mcg/mL; MIC90, 1 mcg/mL). MIC values for
other antibiotics are reported in Supplementary Table 1.
The total median duration of OMC (IQR) was 6.2 (4.2–11.0)
months, with the median duration of follow-up post-OMC initiation (IQR) being 5.1 (3.4–7.2) months. All patients received ≥2
companion antibiotics, with the most common being amikacin
(8/12; 66.7%), imipenem (5/12; 41.7%), linezolid/tedizolid
(5/12; 41.7%), azithromycin (4/12; 33.3%), and/or clofazimine
(4/12; 33.3%). Interestingly, 2 patients received TIG concomitantly with OMC. Oral therapy was strictly utilized in all cases,
with a loading dose of 450 mg once daily on days 1 and 2 used
for initiation of therapy in 2/12 (16.7%) patients, while most patients did not receive a loading dose on initiation and received a
maintenance dose of 300 mg once daily (10/12; 83.3%).
Clinical success occurred in 9/12 (75.0%) cases. Failures involved 3 cases with radiographic fibrocavitary and nodular
bronchiectatic (plus dissemination) sources and skin and soft
tissue sources. Other clinical and composite end point characteristics can be found in Table 1. The primary reasons for OMC
utilization were related to antimicrobial resistance to previous
antibiotic(s) (8/12; 66.7%), previous antibiotic failure (6/12;
50.0%), ease of administration (6/12; 50.0%), and oral bioavailability of OMC (6/12; 50.0%).
Three patients experienced an AE while on therapy. One patient experienced a gastrointestinal AE (nausea/vomiting/diarrhea), and the OMC dose was reduced from 300 mg daily to
150 mg twice daily, with improvement in symptoms. Another
patient experienced serum creatinine increase ≥0.5 mg/dL;
OMC was temporarily discontinued, and this AE resolved. The
third patient experienced AST/ALT elevations >3× the upper
limit of normal; OMC was continued, despite these laboratory
abnormalities, and the abnormalities resolved.
DISCUSSION

We report the largest real-world, observational, multicenter
description of early treatment outcomes for patients treated
with OMC for pulmonary and extrapulmonary M. abscessus
infections with promising results. Due to the in vitro activity of
OMC against M. abscessus and the available oral formulation,
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Microbiologic relapse was defined as 2 consecutive cultures
positive for the same pathogen isolated from index culture following sputum culture conversion (respiratory) or microbiologic clearance (nonrespiratory). Sputum culture conversion
was defined as having at least 3 consecutive negative sputum
NTM cultures over 12 months. Microbiologic clearance was
defined as having any negative culture following positive
index culture (nonrespiratory). The Clinical and Laboratory
Standards Institute (CLSI) susceptibility breakpoints were
applied, when applicable, for interpretation of MIC values,
while the FDA antibacterial susceptibility interpretive criteria
were used when information was not available via CLSI [8,
9]. Combination therapy was defined as any antibiotic used in
tandem with OMC for ≥28 days. All adverse effects while on
OMC were reported, although they could not be fully attributed to OMC due to combination regimens. Descriptive statistics were utilized for analysis using IBM SPSS software, version
26.0 (SPSS, Inc., Chicago, IL, USA).
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given the rarity of this disease, these data reflect pragmatic
outcomes that can be useful for clinicians with limited to no
options for M. abscessus treatment, even without the full microbiologic picture. Next, all patients were on ≥2 additional
antimicrobials; therefore, analysis of the direct response
of OMC is difficult. However, this is also the case with any
antimicrobial used within a combination regimen. Given the
multicenter analysis of our study and the complexities of performing in vitro susceptibility with novel antimicrobials, we
were unable to perform MIC testing for OMC on the majority
of the clinical M. abscessus isolates to determine initial susceptibility, and the possibility of development of OMC resistance
while on therapy remains.
Despite these limitations, this is the largest real-world observational description reporting the experience of early treatment
with OMC for M. abscessus within multiple infectious sites.
A ≥3-month follow-up evaluating OMC therapy by NTMtreating clinicians was required for inclusion in this analysis,
which is a strength compared with other retrospective observational studies. Also, OMC was studied in some patients who
had been treated with numerous antibiotics without success
over long intervals of time. Finally, although MICs for OMC
were only reported in 8.3% of isolates, MICs for TIG were reported in 91.7% of isolates, and previous reports have shown a
high correlation between the 2 antibiotics for M. abscessus [5,
6]. While these early experiences with OMC for M. abscessus
are important to document, prospective studies and larger realworld analyses are urgently needed for these difficult-to-treat
infections.
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it is expected that the medical community would have elevated
curiosity about the use of OMC for patients with M. abscessus.
Our results show similar (or slightly higher) preliminary results congruent with smaller reports of OMC and with other
agent(s) used for M. abscessus infections, both in index and refractory disease [7, 10, 11]. Although the OMC treatment in
its entirety was not included (as treatment is still ongoing for
the majority of cases), no NTM-treating clinician discontinued
OMC due to concerns of failure, with a current median OMC
duration of 6.2 months. Furthermore, incidence rates of possible AEs due to OMC were relatively similar to those in the
phase 3 trials for OMC and other real-world analyses of novel
tetracyclines, despite much longer durations of exposure in this
case series [12, 13].
An important therapeutic for NTM infections is macrolides
(if susceptible), which are subject to inducible resistance
via the erm gene and prolongation of the QTc interval [14].
Importantly, OMC is not impacted by functional erm gene expression and has not been shown to cause clinically significant
QTc prolongation. Given the lack of some clinical laboratories
performing subspeciation or erm gene detection (highlighted
in this analysis with conduction in 58.3% and 75.0%, respectively), OMC could provide a viable oral alternative option for
those clinicians and sites without the complete microbiological
picture.
Tigecycline and ERV have demonstrated similar in vitro activity against isolates of M. abscessus; however, both antibiotics
are only available in intravenous formulations and are dosed
twice daily, which is not ideal for prolonged treatment courses,
and are associated with significant gastrointestinal AEs. OMC
is dosed once daily and has shown fewer gastrointestinal AEs
than TIG or ERV (8.3% in this analysis). Importantly, reported
MIC90 values of ERV against M. abscessus (1 mcg/mL) are
higher than the current FDA breakpoint for Enterobacterales,
while reported MIC90 values for OMC against M. abscessus have
been reported to be 2-fold lower than their current FDA breakpoint [5, 9].
This report has obvious limitations. First, this was a retrospective, observational case series with a small number of patients and the possibility of selection bias. Inclusion criteria
for our analysis required relatively short durations of OMC
exposure and follow-up (≥3 months) relative to traditional
treatment durations associated with M. abscessus; therefore,
although the median duration of OMC was 6.2 months, the
duration of OMC exposure as it relates to outcomes may
have been inadequate to detect a more (or less) favorable response. We included both pulmonary and extrapulmonary
cases of NTM infection, the outcomes of which may be difficult to compare directly based on potential differences in
nonpharmacological management (eg, removal of device in
extrapulmonary cases). Also, subspeciation and functional
erm gene detection were not available in all cases. However,

this article, take responsibility for the integrity of the work as a whole, and
have given their approval for this version to be published.
Patient consent. This study does not include factors necessitating patient consent. Furthermore, the design of the work has been approved by
local ethical committees.
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